期刊
JOURNAL OF INFECTIOUS DISEASES
卷 222, 期 12, 页码 1946-1950出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa518
关键词
dengue; dengue hemorrhagic fever; antibody-dependent enhancement (ADE); vaccine adverse events; coronavirus; SARS-CoV-2; immunopathology; vaccine; hypersensitivity; T cells
Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infections? This is unlikely because coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE disease exemplified by dengue viruses (DENV). In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages. Severe disease centers on older persons with preexisting conditions and not infants or individuals with previous coronavirus infections. Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in humans given inactivated measles or respiratory syncytial virus vaccines. Safe and effective COVID-19 vaccines must avoid VAH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据